Forty Seven, Inc. is a clinical-stage immuno-oncology company that is developing therapies targeting cancer immune evasion pathways and specific cell …

Read more. In March 2020, the company announced it would acquire Forty Seven Inc. for $95.50 a share ($4.9 billion in total). Within the next few days, the magnitude of Gilead's interest in Forty Seven should become clear. On April 7, 2020, Gilead completed acquisition of Forty Seven, Inc. for "$95.50 per share, net to the seller in cash, without interest, or approximately $4.9 billion in the aggregate." Forty Seven Inc. (NASDAQ: FTSV) shares skyrocketed on Monday after the company announced that it would be acquired by Gilead Sciences Inc. (NASDAQ: GILD). Gilead Completes Acquisition of Forty Seven, Inc. Gilead Sciences, Inc. (Nasdaq: GILD) today announced the completion of the previously announced transaction for Toro Merger Sub, Inc… On March 3, Gilead Sciences (NASDAQ:GILD) announced it had reached an agreement to buy Forty Seven (NASDAQ:FTSV) for approximately $4.9 billion in cash. Forty Seven Inc. (NASDAQ:FTSV) +23% after-hours following a Bloomberg report that Gilead Sciences (NASDAQ:GILD) has approached the company with a takeover offer.Gilead and Forty Seven are discussing s Gilead Sciences has agreed to acquire Forty Seven for $4.9 billion cash, in a deal intended to boost the buyer’s immuno-oncology R&D pipeline—anchored by Forty Seven’s lead … Forty Seven, Inc. is a clinical-stage immuno-oncology company that is developing therapies targeting cancer immune evasion pathways and specific cell targeting approaches based on technology licensed from Stanford University. Gilead Science Inc.’s $4.9 billion acquisition of Forty Seven Inc. more than doubled the latter’s stock (NASDAQ:FTSV) as it dramatically rose 61.5% in midday trading Monday. march 2 (reuters) - forty seven inc: * gilead to acquire forty seven for $4.9 billion * gilead sciences inc - deal for $95.50 per share * forty seven inc - … Forty Seven, Inc. is a clinical-stage immuno-oncology company that is developing therapies targeting cancer immune evasion pathways and specific cell targeting approaches based on technology licensed from Stanford University. On April 7, 2020, Gilead completed acquisition of Forty Seven, Inc. for "$95.50 per share, net to the seller in cash, without interest, or approximately $4.9 billion in the aggregate." March 2 (Reuters) - Gilead Sciences Inc GILD.O said on Monday it would buy cancer drug developer Forty Seven Inc FTSV.O for $4.9 billion in cash.